Pathophysiological Basis

  • Duchenne Muscular Dystrophy (DMD) is an X-linked recessive disorder caused by out-of-frame deletions (60–70%), duplications (5–10%), or nonsense/point mutations in the DMD gene on chromosome Xp21.
  • Complete absence of the cytoskeletal protein dystrophin disrupts the dystrophin-glycoprotein complex (DGC) linking the intracellular actin cytoskeleton to the extracellular matrix.
  • Sarcolemmal micro-tears during muscle contraction trigger massive calcium influx, calpain activation, chronic myofiber necrosis, chronic inflammation, and progressive replacement of muscle by fibrofatty connective tissue.
  • Disease-modifying therapies (DMTs) aim to restore truncated or full-length dystrophin, skip mutated exons, bypass premature stop codons, or block downstream fibrosis and muscle degeneration.

1. Glucocorticoids And Dissociative Steroids

Standard Glucocorticoids

  • Prednisolone ($0.75\text{ mg/kg/day}$) or Deflazacort ($0.9\text{ mg/kg/day}$) remains foundational standard care for all DMD patients aged $\ge 4$ years.
  • Mechanism: Inhibits NF-$\kappa$B-mediated inflammation, reduces cytotoxic T-cell infiltration, and up-regulates utrophin; prolongs independent ambulation by 2 to 3 years.
  • Adverse effects: Growth stunting, cushingoid habitus, osteoporosis, vertebral compression fractures, cataracts, and behavioral changes.

Vamorolone (Agamree) - Dissociative Steroid

  • First-in-class "dissociative" synthetic steroid approved for DMD patients aged $\ge 2$ years.
  • Mechanism: Retains anti-inflammatory transrepression (binding the glucocorticoid receptor and inhibiting NF-$\kappa$B), but does not activate transactivation (which drives classic steroid-response element gene transcription responsible for adverse metabolic events).
  • Dose: $6\text{ mg/kg/day}$ orally once daily with a meal (maximum 300 mg/day).
  • Clinical Advantage: Preserves motor function equivalent to standard corticosteroids while significantly mitigating growth deceleration, bone mineral density loss, and metabolic toxicity.

2. Micro-Dystrophin Gene Therapy: Elevidys

  • Agent: Delandistrogene moxeparvovec-rokl (Elevidys).
  • Vector Mechanism: Non-replicating recombinant Adeno-Associated Virus serotype rh74 (AAVrh74) delivering an engineered micro-dystrophin transgene containing critical rod domains and the cysteine-rich domain driven by a muscle-specific promoter (MHCK7).
  • Administered as a single intravenous infusion ($1.33 \times 10^{14}\text{ vector genomes/kg}$).

2024–2025 FDA Label Expansion And Indications

  • In June 2024, the FDA expanded approval to include both ambulatory and non-ambulatory DMD patients aged $\ge 4$ years with a confirmed mutation in the DMD gene.
  • Full traditional approval was granted for ambulatory patients, and accelerated approval for non-ambulatory patients based on robust micro-dystrophin protein expression.

Critical Contraindications And Safety Boxed Warnings

  • Absolute Contraindication: Any deletion in exon 8 and/or exon 9 in the DMD gene. Patients with these deletions develop severe, life-threatening immune-mediated myositis and cross-reactive T-cell responses against the recombinant micro-dystrophin transgene.
  • Acute Serious Liver Injury: Immune-mediated hepatitis; mandates weekly liver function tests for the first 3 months and high-dose corticosteroid coverage (oral prednisolone $1\text{ mg/kg/day}$ initiated 1 day before infusion and continued for at least 60 days).
  • Immune-Mediated Myocarditis: Monitor baseline troponin-I and ECG; repeat troponin-I weekly for the first month post-infusion.
  • AAVrh74 Antibody Titers: Anti-AAVrh74 antibody titers must be $\le 1:400$ prior to infusion.

3. Downstream Fibrosis Inhibitor: Givinostat (Duvyzat)

  • First oral non-steroidal Histone Deacetylase (HDAC) inhibitor approved for all DMD genetic variants in patients aged $\ge 6$ years.
  • Pathophysiological Target: In dystrophic muscle, aberrant intracellular calcium hyper-activates HDACs, silencing muscle regenerative genes and promoting fibrofatty replacement.
  • Givinostat inhibits HDACs, reducing muscle inflammation, blocking fibrofatty scar tissue accumulation, and promoting muscle fiber regeneration.
  • Dosing: Weight-tiered twice-daily oral suspension taken with food.
  • Monitoring Requirements:
    • Baseline complete blood counts: Risk of dose-dependent thrombocytopenia and leukopenia (monitor platelets and ANC every 2–4 weeks initially).
    • Fasting serum triglycerides (risk of hypertriglyceridemia).
    • Periodic baseline and follow-up ECG to monitor for QTc prolongation.

4. Mutation-Specific Genetic Therapies

A. Antisense Oligonucleotides (Exon Skipping)

  • Synthetic phosphorodiamidate morpholino oligomers (PMOs) that bind to pre-mRNA during splicing, masking targeted exons and restoring the open reading frame.
  • Converts a severe out-of-frame DMD mutation into an in-frame, milder Becker-like dystrophin protein.
  • Delivered as weekly intravenous infusions.
DrugTarget ExonTarget Patient PopulationMechanism
Eteplirsen (Exondys 51)Exon 51Amenable to exon 51 skipping ($\approx 13\text{–}14\%$ of DMD)Skips exon 51 to restore reading frame
Golodirsen (Vyondys 53)Exon 53Amenable to exon 53 skipping ($\approx 8\text{–}10\%$ of DMD)Skips exon 53 to restore reading frame
Viltolarsen (Viltepso)Exon 53Amenable to exon 53 skipping ($\approx 8\text{–}10\%$ of DMD)Higher micro-dystrophin expression levels
Casimersen (Amondys 45)Exon 45Amenable to exon 45 skipping ($\approx 8\%$ of DMD)Skips exon 45 to restore reading frame

B. Nonsense Mutation Read-Through (Ataluren)

  • Ataluren (Translarna): Oral small molecule indicated for DMD caused by nonsense mutations (premature stop codons: UAA, UAG, UGA), accounting for 10% to 15% of cases.
  • Enables ribosomes to read through premature stop codons, allowing translation of full-length functional dystrophin. Taken orally 3 times daily.

Comparative Overview Of DMD Disease-Modifying Therapies

Modality / DrugTarget DMD PopulationPrimary Mechanism Of ActionKey Adverse Events / Monitoring
VamoroloneAll patients $\ge 2$ yearsDissociative steroid: transrepression without transactivationAdrenal suppression on withdrawal; lower bone/growth toxicity
GivinostatAll patients $\ge 6$ yearsOral pan-HDAC inhibitor blocking muscle fibrofatty substitutionThrombocytopenia, hypertriglyceridemia, QTc prolongation
ElevidysAmbulatory & non-ambulatory $\ge 4$ yearsAAVrh74-mediated micro-dystrophin gene transferAcute liver injury, troponin-I elevation, immune myositis
Exon-Skipping ASOsSpecific exon deletions (51, 53, 45)PMO-mediated pre-mRNA splicing frame restorationRenal tubular toxicity, proteinuria, requires weekly IV lines
AtalurenNonsense mutations onlyRibosomal read-through of premature termination codonsGastrointestinal upset, elevated transaminases, dyslipidemia